Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
BioDelivery Sciences Internati (NQ: BDSI)
4.740 USD  -0.160 (-3.27%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about BioDelivery Sciences Internati
 
< Previous 1 2 3 4 5 6 Next >
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
May 09, 2013
NDA filing for BUNAVAIL on track for mid-summer 2013 Read More
from PR Newswire
BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
May 07, 2013
from PR Newswire
BioDelivery Sciences Appoints Thomas W. D'Alonzo to Board of Directors
April 29, 2013
from PR Newswire
BioDelivery Sciences Expands Product Pipeline with Acquisition of Patented Topical Clonidine Gel for the Treatment of Painful Diabetic Neuropathy
March 26, 2013
Completed Phase 2 study demonstrated efficacy in a pain condition with significant unmet need Read More
from PR Newswire
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
March 18, 2013
NDA filing for BEMA Buprenorphine/Naloxone (BUNAVAIL) on track for mid-2013 Read More
from PR Newswire
BioDelivery Sciences to Present at the 25th Annual ROTH Conference
March 13, 2013
from PR Newswire
BioDelivery Sciences to Present at the Cowen and Company 33rd Annual Health Care Conference
March 01, 2013
from PR Newswire
INVESTOR ALERT: Former Attorney General of Louisiana and Kahn Swick & Foti, LLC Investigate BioDelivery Sciences International, Inc., Following Notice of Non-Reliance of Financial Statements and Resta
February 28, 2013
from Business Wire News Releases
BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event
February 27, 2013
from PR Newswire
BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
February 05, 2013
from PR Newswire
BioDelivery Sciences Announces Completion of BNX Safety Study
January 22, 2013
Study shows favorable safety profile in opioid dependent patients transitioning from Suboxone Read More
from PR Newswire
BioDelivery Sciences Announces Hiring of George Ng as General Counsel
December 17, 2012
from PR Newswire
BioDelivery Sciences Announces $40 Million Registered Financing
November 28, 2012
Financing expected to fund completion of BEMA Buprenorphine Phase 3 program and progress BNX to NDA submission Read More
from PR Newswire
BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
November 19, 2012
from PR Newswire
BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
November 08, 2012
Positive outcome achieved from pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence; NDA filing in 2Q 2013 Read More
from PR Newswire
BioDelivery Sciences Reaffirms its Strengthened Position Following Reexamination of MonoSol Patents
October 18, 2012
from PR Newswire
MonoSol Rx Defeats BioDelivery Sciences International's Reexamination Challenges to MonoSol Rx's PharmFilm(R) Patents
October 16, 2012
New USPTO Patent Claims Strengthens Robust IP Portfolio Read More
from GlobeNewswire News Releases
BioDelivery Sciences Announces the Launch of BREAKYL (BEMA Fentanyl) in the E.U.
October 15, 2012
Launch triggers final E.U. milestone payment of $2.5 million to BDSI Read More
from PR Newswire
MAS Capital Group Newsletter
September 20, 2012
from PR Newswire
BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
September 13, 2012
NDA target remains on course for the second quarter of 2013 Read More
from PR Newswire
BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
August 29, 2012
from PR Newswire
BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
August 20, 2012
Results on target to be released in September Read More
from PR Newswire
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
August 09, 2012
Pivotal clinical studies underway for BEMA Buprenorphine for chronic pain and BNX for opioid dependence Read More
from PR Newswire
BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
August 08, 2012
from PR Newswire
BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
August 02, 2012
Phase 3 program includes two efficacy studies - one in opioid naive and one in opioid experienced patient populations Read More
from PR Newswire
BioDelivery Sciences to Present at the JMP Securities Healthcare Conference
July 09, 2012
from PR Newswire
BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
June 28, 2012
Results of the FDA recommended trial demonstrate dose proportionality ahead of the forthcoming pivotal pharmacokinetic study versus Suboxone Read More
from PR Newswire
BioDelivery Sciences Added to the Russell 3000 and Russell 2000 Indexes
June 25, 2012
from PR Newswire
BioDelivery Sciences to Present at the Jefferies 2012 Global Healthcare Conference
May 31, 2012
from PR Newswire
BioDelivery Sciences Receives $2.5 Million Milestone from Meda for BREAKYL in E.U.
May 21, 2012
Milestone payment received in conjunction with granting of first country registration and pricing approval Read More
from PR Newswire
< Previous 1 2 3 4 5 6 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here